Estrogen Receptors: How Do They Signal and What Are Their Targets
Top Cited Papers
- 1 July 2007
- journal article
- review article
- Published by American Physiological Society in Physiological Reviews
- Vol. 87 (3), 905-931
- https://doi.org/10.1152/physrev.00026.2006
Abstract
During the past decade there has been a substantial advance in our understanding of estrogen signaling both from a clinical as well as a preclinical perspective. Estrogen signaling is a balance between two opposing forces in the form of two distinct receptors (ERα and ERβ) and their splice variants. The prospect that these two pathways can be selectively stimulated or inhibited with subtype-selective drugs constitutes new and promising therapeutic opportunities in clinical areas as diverse as hormone replacement, autoimmune diseases, prostate and breast cancer, and depression. Molecular biological, biochemical, and structural studies have generated information which is invaluable for the development of more selective and effective ER ligands. We have also become aware that ERs do not function by themselves but require a number of coregulatory proteins whose cell-specific expression explains some of the distinct cellular actions of estrogen. Estrogen is an important morphogen, and many of its proliferative effects on the epithelial compartment of glands are mediated by growth factors secreted from the stromal compartment. Thus understanding the cross-talk between growth factor and estrogen signaling is essential for understanding both normal and malignant growth. In this review we focus on several of the interesting recent discoveries concerning estrogen receptors, on estrogen as a morphogen, and on the molecular mechanisms of anti-estrogen signaling.Keywords
This publication has 104 references indexed in Scilit:
- Meta-analyses of adjuvant therapies for women with early breast cancer: the Early Breast Cancer Trialists’ Collaborative Group overviewAnnals of Oncology, 2006
- Identification, cloning, and expression of human estrogen receptor-α36, a novel variant of human estrogen receptor-α66Biochemical and Biophysical Research Communications, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Scaffold attachment factors SAFB1 and SAFB2: Innocent bystanders or critical players in breast tumorigenesis?Journal of Cellular Biochemistry, 2003
- Breast cancer and hormone-replacement therapy in the Million Women StudyThe Lancet, 2003
- Evaluation of oestrogen receptor β wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancersEuropean Journal of Cancer, 2002
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- An Estrogen Receptor β Isoform That Lacks Exon 5 Has Dominant Negative Activity on both ERα and ERβBiochemical and Biophysical Research Communications, 2000
- Regulated expression of estrogen receptor α and β mRNA in granule cells during development of the rat cerebellumDevelopmental Brain Research, 1999
- Cloning and Characterization of Human Estrogen Receptor β IsoformsBiochemical and Biophysical Research Communications, 1998